PET/CT with 18F-Fluoroestradiol in First Diagnosed Breast Cancer. A Pilot Study
Open Access
- 14 December 2023
- journal article
- research article
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 6 (4) , 18-25
Abstract
Purpose: To evaluate the informativity of PET/CT with 18F-FES in determining estrogen receptor (ER) positivity in breast tumor tissue, as well as in regional lymph nodes or distant metastatic foci. Material and methods: The data of 30 patients who underwent PET/CT with 18F-FES performed at the stage of primary diagnosis were retrospectively analyzed. The study included patients before the start of specific treatment or on the background of neoadjuvant hormone therapy, with previously determined expression of ER according to the results of IGC. 14 patients underwent 18F-FDG PET/CT with 2–7 days difference between both PET/CT. Results: In our study, the mean SUVmax value in the primary tumor focus was 4.8, the lowest SUVmax = 1.61, and the highest SUVmax = 18.86. 18F-FES accumulation considered suspicious for metastatic lesion in axillary lymph nodes on the affected side was detected in 16 patients (56 %), mean SUVmax = 5.2, lowest SUVmax = 0.99, highest SUVmax = 11.54. On subsequent histological examination, tumor changes in axillary lymph nodes were confirmed in 16/16 patients. Conclusion: PET/CT with 18F-FES is a diagnostic method for noninvasive evaluation of ER expression in tumor foci, which can complement the data of traditional diagnostic methods and has a significant clinical potential. In our study, the results of PET/CT with 18F-FES coincided with the data of immunohistochemical study in 100 % of cases.Keywords
This publication has 25 references indexed in Scilit:
- 18F-Fluoroestradiol PET: Current Status and Potential Future Clinical ApplicationsJournal of Nuclear Medicine, 2016
- 18F-FDG PET/CT for Monitoring of Treatment Response in Breast CancerJournal of Nuclear Medicine, 2016
- Clinical management of breast cancer heterogeneityNature Reviews Clinical Oncology, 2015
- Measuring Residual Estrogen Receptor Availability during Fulvestrant Therapy in Patients with Metastatic Breast CancerCancer Discovery, 2015
- PET imaging of oestrogen receptors in patients with breast cancerThe Lancet Oncology, 2013
- Feasibility and Predictability of Perioperative PET and Estrogen Receptor Ligand in Patients with Invasive Breast CancerJournal of Nuclear Medicine, 2013
- Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor ProgressionJournal of Clinical Oncology, 2012
- Functional Activation of the Estrogen Receptor-α and Aromatase by the HDAC Inhibitor Entinostat Sensitizes ER-Negative Tumors to LetrozoleCancer Research, 2011
- ONCOPOOL – A European database for 16,944 cases of breast cancerEuropean Journal of Cancer, 2010
- Meta-analysis of human cancer microarrays reveals GATA3 is integral to the estrogen receptor alpha pathwayMolecular Cancer, 2008